IRLAB to hold four presentations at scientific congress AD/PD™ 2023
Gothenburg, Sweden, March 17, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.
[mfn_before_post]
Gothenburg, Sweden, March 17, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.
One abstract has been selected to be presented as an oral presentation during the session Symposium: Exploring new targets in AD, PD and LBD:
| Abstract 735 | |
| Title: | IRL942 – A NOVEL COMPOUND WITH PROCOGNITIVE PROPERTIES ADDRESSING CORTICAL IMPAIRMENT IN PARKINSON'S DISEASE |
| Authors: | S. Hjorth1,2, J. Tedroff1, N. Waters1, C. Sonesson1, D. Andersson1, F. Pettersson1, S. Waters1; 1. Integrative Research Laboratories Sweden AB, IRLAB, Göteborg, Sweden, 2. Pharmacilitator, AB, Vallda, Sweden |
| Date and time: | April 1, 2023, at 12:25 – 12:40 |
Three abstracts have been accepted as poster presentations and will be available to view online and onsite during the full length of the congress:
| Abstract 1026 | |
| Title: | IN VIVO SYSTEMS RESPONSE PROFILE MAPPING OF NOVEL CANDIDATE DRUGS IN DEVELOPMENT FOR TREATMENT OF SYMPTOMS RELATED TO CORTICAL IMPAIRMENT IN PARKINSON’S DISEASE |
| Authors: | S. Waters1, J. Tedroff1, C. Sonesson1, S. von Unge1, S. Hjorth1,2, J. Kullingsjö1, D. Andersson1, F. Pettersson1, N. Waters1; 1. Integrative Research Laboratories Sweden AB, IRLAB, Göteborg, Sweden, 2. Pharmacilitator, AB, Vallda, Sweden |
| Abstract 2100 | |
| Title: | ISP – A TRANSLATIONAL APPROACH FOR CNS DRUG DISCOVERY APPLIED IN PARKINSON’S DISEASE (PD) |
| Authors: | J. Tedroff1, S. Waters1, C. Sonesson1, D. Andersson1, S. Hjorth1,2, P. Svensson1, N. Waters1; 1. Integrative Research Laboratories Sweden AB, IRLAB, Göteborg, Sweden, 2. Pharmacilitator, AB, Vallda, Sweden |
| Abstract 2180 | |
| Title: | LESSONS LEARNED REGARDING LIGAND INDUCED CONFORMATIONAL CHANGES AND STRUCTURE-ACTIVITY RELATIONSHIPS FROM ALL RECENTLY DETERMINED GPCR STRUCTURES OF MONOAMINERGIC LIGAND-RECEPTOR COMPLEXES |
| Authors: | P. Svensson, M. Malo, F. Wallner; Integrative Research Laboratories Sweden AB, IRLAB, Göteborg, Sweden |
The presentations will also be available on IRLAB’s website following the presentations.
For more details about the AD/PD™ 2023 congress, please visit: https://adpd.kenes.com/
[mfn_after_post]